GlycoNex Advances Novel Glycan-Targeted ADC GNX1021 for HER2-Low Gastric Cancer
核心洞察
GlycoNex announced that preclinical research on its first-in-class antibody-drug conjugate GNX1021 has been accepted for presentation at the AACR-NCI-EORTC International Conference.
GNX1021 is engineered to target branched Lewis B/Y glycans, which are highly expressed in gastric and epithelial tumors but have limited expression in healthy tissue.
The company plans to submit an Investigational New Drug application in the first quarter of 2026 for a first-in-human clinical trial of GNX1021.
GlycoNexSearch company, Inc., a clinical-stage biotechnology company focused on glycan-directed cancer immunotherapies, announced that preclinical research on its first-in-class antibody-drug conjugate (ADC) GNX1021Search drug has been accepted for presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 22-26, 2025, in Boston, Massachusetts.
Novel Glycan-Targeting Mechanism
The abstract, titled "Targeting branched Lewis B/Y glycans with GNX1021Search drug: A novel ADC approach for HER2Search term-low gastric cancer," describes preclinical work characterizing GNX1021's innovative glycan-targeting mechanism. GNX1021 is engineered to recognize branched Lewis B/Y, a tumor-associated glycan highly expressed in gastric and other epithelial tumors but with limited expression in healthy tissue, potentially enabling a new level of tumor selectivity.
This approach represents a significant advancement in targeting gastric cancer, particularly in HER2Search term-low cases where treatment options remain limited. The selective expression pattern of branched Lewis B/Y glycans offers the potential for improved therapeutic targeting while minimizing damage to healthy tissues.
Clinical Development Timeline
GlycoNexSearch company anticipates submitting an Investigational New Drug (IND) application in the first quarter of 2026 for a first-in-human clinical trial of GNX1021Search drug. The program builds on GlycoNex's proprietary GlycoSH antibody bank and extensive expertise in glycan-directed antibody and ADC development.
Company Pipeline and Platform
GlycoNexSearch company possesses a robust pipeline led by GNX102Search drug, a humanized monoclonal antibody designed to target abnormal sugar molecules in cancer cells. GNX102 has successfully completed Phase 1 clinical trials with data demonstrating excellent safety and promising efficacy. The company is also advancing a portfolio of antibody-drug conjugates that precisely attack cancer cells while sparing healthy tissue.
The Taiwan-based biotechnology company focuses on developing glycan-directed cancer immunotherapies that effectively inhibit tumor growth while minimizing side effects. GlycoNexSearch company is headquartered in New Taipei City, Taiwan.